80% Capital Reduction (5→1 Share Consolidation): Capital from 9.09B to 1.82B KRW and Election of 3 Inside Directors

Capital reduction of 80% (consolidation of 5 common shares into 1) to improve financial structure by covering deficits. Post-reduction: shares from 90,882,907 to 18,176,581; capital from KRW 90,882,907,000 to KRW 18,176,581,000. Record date for reduction: June 14, 2026.
Agenda includes election of three inside directors: Lee Jun-kyu, Jeon Kyung-ha, Kim Hoon-beom.
Proxy solicitation by GeneOne Life Science; shareholder meeting date: April 29, 2026; solicitation period starts April 15, 2026. Electronic proxy and e-voting available.